Prophylactic High-Dose Oral-N-Acetylcysteine Does Not Prevent Atrial Fibrillation after Heart Surgery A Prospective Double Blind Placebo-Controlled Randomized Clinical Trial

Prophylactic High-Dose Oral-N-Acetylcysteine Does Not Prevent Atrial Fibrillation after Heart Surgery A Prospective Double Blind Placebo-Controlled Randomized Clinical Trial


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: بابک کاظمی اربط , فریبرز اکبرزاده , ناصر صفائی آغبلاغ , علیرضا یعقوبی گلوردی , کامران شادور

کلمات کلیدی: N-acetylcystein, postoperative atrial fibrillation, coronary artery bypass, open heart surgery

نشریه: 26562 , 10 , 36 , 2013

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بابک کاظمی اربط
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات قلب وعروق
کد مقاله 70012
عنوان فارسی مقاله Prophylactic High-Dose Oral-N-Acetylcysteine Does Not Prevent Atrial Fibrillation after Heart Surgery A Prospective Double Blind Placebo-Controlled Randomized Clinical Trial
عنوان لاتین مقاله Prophylactic High-Dose Oral-N-Acetylcysteine Does Not Prevent Atrial Fibrillation after Heart Surgery A Prospective Double Blind Placebo-Controlled Randomized Clinical Trial
ناشر 6
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Aims: Postoperative atrial fibrillation (POAF) following cardiac surgery is a frequent complication with multifactorial etiologies. Recently inflammation due to enhanced oxidative stress has been implicated in its pathogenesis. N-acetylcysteine (NAC) is a promising and novel antioxidant agent. The purpose of this study was to evaluate the efficacy of high-dose oral-NAC for prevention of POAF. Methods: Two hundred and forty patients were randomized in this prospective, double blind placebocontrolled trial to either 1,200-mg oral-NAC two times a day (n = 120) or placebo (n = 120) starting 48 hours before and up to 72 hours after open heart surgery. Results: The mean age was about 60 years, and 75% were male. Patients in the NAC group were older, with higher percentage of acute coronary syndrome, hypercholesterolemia, and left internal mammary artery use. Coronary involvement and hypertension were more prevalent in the placebo group. All other baseline patient characteristics were similar between groups. Overall POAF developed in 13.8% of the patients. There was no difference in the incidence of POAF between the NAC vs placebo groups (11.7% vs 15.8%, respectively; P = 0.34). Postoperative hospital stay, morbidity, and mortality were similar in both groups. Conclusions: Prophylactic high-dose oral-NAC begun 2 days before open heart surgery and continued for 5 days, and had no significant effect on the incidence of POAF, in-hospital stay, and postoperative morbidity or mortality. (PACE 2013; 36:1211–1219)

نویسندگان
hide/show

نویسنده نفر چندم مقاله
بابک کاظمی اربطاول
فریبرز اکبرزادهدوم
ناصر صفائی آغبلاغسوم
علیرضا یعقوبی گلوردیچهارم
کامران شادورپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
(IF=1.31) Prophylactic High-Dose Oral-N-Acetylcysteine Does Not Prevent Atrial Fibrillation after Heart Surgery.pdf1398/09/13245688دانلود